You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Optimizing Management of Advanced Gastric Cancer: Knowing When and How to Use Immune Checkpoint Inhibitors

  • Authors: Jennifer L. Zadlo, PharmD, BCOP; Harry H. Yoon, MD, MHS; Sharon L. Cavone, RN, BSN, OCN
  • CME / CE Released: 10/19/2022
  • Valid for credit through: 4/19/2023
Start Activity

  • Credits Available

    Physicians - maximum of 2.00 AMA PRA Category 1 Credit(s)™

    Nurses - 2.00 ANCC Contact Hour(s) (2 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for oncologists, oncology nurses and nurse practitioners, and oncology pharmacists.

Provide oncologists, oncology nurses, and oncology pharmacists with advanced and up-to-date knowledge of the evolving use of immune checkpoint inhibitors in gastric cancer, including assessing biomarkers for appropriate and timely therapy initiation.

Upon completion of this activity, participants will:

  1. Describe emerging evidence for immune checkpoint inhibitors in advanced gastric cancer
  2. Recognize appropriate biomarker assessment for timely initiation of immune checkpoint inhibitors for advanced gastric cancer
  3. Develop a patient-specific treatment plan for a patient with advanced gastric cancer
  4. Formulate approaches to optimally manage a patient with advanced gastric cancer on immune checkpoint inhibitors


Disclosures

Disclosure of Unlabeled Use and Disclaimer:

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Postgraduate Institute for Medicine (PIM), or Bristol Myers Squibb. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use (review of any applicable manufacturer's product information), and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.


Faculty

  • Jennifer L. Zadlo, PharmD, BCOP

    Oncology Clinical Pharmacy Specialist
    Gastrointestinal Medical Oncology and Endocrine Neoplasias
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Jennifer L. Zadlo, PharmD, BCOP, has no relevant financial relationships.

  • Harry H. Yoon, MD, MHS

    Chair, Gastroesophageal Cancer Disease Group
    Mayo Clinic Comprehensive Cancer Center
    Consultant, Department of Oncology
    Mayo Clinic
    Associate Professor of Oncology
    Mayo Clinic College of Medicine
    Rochester, Minnesota

    Disclosures

    Harry H. Yoon, MD, MHS, has the following relevant financial relationships:
    Consultant or advisor for: The Mayo Foundation received funds for his work with ALX Oncology; Astellas; AstraZeneca; BeiGene; Bristol Myers Squibb; Macrogenics; Merck; OncXerna; Zymeworks
    Grants from: Bristol Myers Squibb
    Other: Participation on a Data Safety Monitoring Board or Advisory Board: ALX Oncology; Astella; AstraZeneca; BeiGene, Bristol Myers Squibb; Macrogenics; Merck; OncXerna; Zymeworks

  • Sharon L. Cavone, RN, BSN, OCN

    Clinical Content Developer
    CARVIVE Systems, Inc.
    Oncology Nurse Navigator (Former)
    PENN Medicine Princeton Healthcare
    Princeton, New Jersey

    Disclosures

    Sharon L. Cavone, RN, BSN, OCN, has no relevant financial relationships.

Additional Planners/Reviewers

The clinical reviewer, Lisa Holle, PharmD, has no relevant financial relationships.

Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

The PIM planners and others have no relevant financial relationships.

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.


Accreditation Statements


In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Postgraduate Healthcare Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

    For Nurses

  • The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Designated for 2.0 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

    Published: September 30, 2022
    Expires: March 30, 2023
    Type of Activity: Application Media: Internet
    Fee Information: There is no fee for this educational activity.
    Estimated time to complete
    activity: 120 minutes

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Optimizing Management of Advanced Gastric Cancer: Knowing When and How to Use Immune Checkpoint Inhibitors

Authors: Jennifer L. Zadlo, PharmD, BCOP; Harry H. Yoon, MD, MHS; Sharon L. Cavone, RN, BSN, OCNFaculty and Disclosures

CME / CE Released: 10/19/2022

Valid for credit through: 4/19/2023

processing....

Assessment Survey

Before you begin, please take this brief survey.